For decades since its inception, mammography has been the leading method for detecting breast cancer. However, a new AI technology called Thermalytix could become a less invasive and less expensive early intervention tool, as shown through its trials of breast cancer screening in India.

Breast Cancer in India

Breast cancer is the most prevalent cancer among women worldwide. It also has the fourth-highest mortality rate out of any cancer. In India specifically, it is a significant issue. Despite having lower incidence levels, the nation continues to have similar or higher mortality rates than Western countries. One of the main contributors to this high rate of mortality is delayed detection.

Health professionals recommended that all females aged 40 and above receive yearly mammograms to screen for breast cancer. However, according to the Longitudinal Aging Study in India, fewer than 2% of the 35,083 women aged above 40 surveyed reported receiving a mammogram in the past two years. Due to this lack of thorough and routine examination, many breast cancers are not diagnosed until they are in advanced stages.

The percentage of women who reported receiving mammograms varies slightly based on socioeconomic status, other preexisting health conditions and place of residence. However, as a whole, access to and use of mammogram technology for breast cancer screening is limited. This is due to high costs and lack of adequate medical equipment and workers in India and other low- and middle-income countries (LMICs).

Predictive Screening With AI

Niramai, a tech company located in Bengaluru, India, has developed an AI technology known as Thermalytix, which detects indicators of breast cancer. Thermalytix uses computer software to analyze thermal imaging of breasts and scan them for abnormal “hot spots, warm spots and vascular patterns” and determine the probability of any malignant lesions.

Since 2016, Niramai has conducted studies on the effectiveness of Thermalytix in different clinics and hospitals across India. Over the past nine years, Niramai has invited more than 16,000 women to participate in clinical trials, improving its Thermalytix technology. Thermalytix was evaluated in terms of sensitivity (ability to identify true positives) and specificity (ability to identify true negatives) in each study.

In every iteration, Thermalytix has consistently scored between 82-98% in sensitivity and 80-88% in specificity. It has already “received regulatory approval in India” and met the health and safety criteria to receive the CE mark in Europe. Thermalytix patients found to be positive or at high risk for breast cancer are always referred to receive further testing with either mammography, MRI or ultrasound technology. However, its effectiveness as an early intervention tool is not to be understated.

Conclusion

As a lower-cost and noninvasive technology, Thermalytix has the potential to make breast cancer screening in India more accessible to the general population. If implemented on a large scale, this technology could “improve overall treatment outcomes” by catching breast cancer before it reaches the later stages.

– Delaney Gouveia

Delaney is based in Newport, RI, USA and focuses on Global Health for The Borgen Project.

Photo: Pexels